Patents by Inventor Val S. Goodfellow

Val S. Goodfellow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyrrolo[2,3-b]pyridines as MLK inhibitors
    Patent number: 9814704
    Abstract: Provided are compounds having an inhibitory effect on Mixed Lineage Kinases. The compounds include substituted pyrrolo[2,3-b]pyridines having Formula IX Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment neuropsychiatric disorders which comprise the inhibition of Mixed Lineage Kinases.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: November 14, 2017
    Assignee: The University of Rochester
    Inventors: Harris A. Gelbard, Stephen Dewhurst, Val S. Goodfellow, Colin J. Loweth, Torsten Wiemann
  • MLK INHIBITORS AND METHODS OF USE
    Publication number: 20160317509
    Abstract: Provided are compounds having an inhibitory effect on Mixed Lineage Kinases. Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment of neuropsychiatric disorders which comprise the inhibition of Mixed Lineage Kinases.
    Type: Application
    Filed: June 3, 2016
    Publication date: November 3, 2016
    Inventors: Harris A. Gelbard, Stephen Dewhurst, Val S. Goodfellow, Colin J. Loweth, Torsten Wiemann
  • MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS
    Publication number: 20160228437
    Abstract: Provided herein are imidazopyridine compounds having an inhibitory effect on mixed lineage kinases (MLKs), methods of their synthesis, and methods of their therapeutic. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and pharmaceutical compositions.
    Type: Application
    Filed: April 20, 2016
    Publication date: August 11, 2016
    Inventors: Val S. Goodfellow, Thong X. Nguyen, Satheesh B. Ravula, Harris A. Gelbard
  • Mixed lineage kinase inhibitors and method of treatments
    Patent number: 9370515
    Abstract: Provided herein are imidazopyridine compounds having an inhibitory effect on mixed lineage kinases (MLKs), methods of their synthesis, and methods of their therapeutic. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and pharmaceutical compositions.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: June 21, 2016
    Assignees: CALIFIA BIO, INC., UNIVERSITY OF ROCHESTER
    Inventors: Val S. Goodfellow, Thong X. Nguyen, Satheesh B. Ravula, Harris A. Gelbard
  • MLK INHIBITORS AND METHODS OF USE
    Publication number: 20160024087
    Abstract: Provided are compounds having an inhibitory effect on Mixed Lineage Kinases. Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment of neuropsychiatric disorders which comprise the inhibition of Mixed Lineage Kinases.
    Type: Application
    Filed: October 6, 2015
    Publication date: January 28, 2016
    Inventors: Harris A. Gelbard, Stephen Dewhurst, Val S. Goodfellow, Colin J. Loweth, Torsten Wiemann
  • Substituted pyrrolo[2,3-B]pyridines as MLK inhibitors
    Patent number: 9181247
    Abstract: Provided are compounds having an inhibitory effect on Mixed Lineage Kinases. The compounds include substituted pyrrolo [2,3b]pyridines having Formula IX Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment of neuropsychiatric disorders which comprise the inhibition of Mixed Lineage Kinases.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: November 10, 2015
    Assignee: The University of Rochester
    Inventors: Harris A. Gelbard, Stephen Dewhurst, Val S. Goodfellow, Colin J. Loweth, Torsten Wiemann
  • MLK INHIBITORS AND METHODS OF USE
    Publication number: 20150105401
    Abstract: Provided are compounds having an inhibitory effect on Mixed Lineage Kinases. Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment of neuropsychiatric disorders which comprise the inhibition of Mixed Lineage Kinases.
    Type: Application
    Filed: October 7, 2014
    Publication date: April 16, 2015
    Applicant: The University of Rochester
    Inventors: Harris A. Gelbard, Stephen Dewhurst, Val S. Goodfellow, Colin J. Loweth, Torsten Wiemann
  • Substituted pyrrolo[2,3-B]pyridines as MLK inhibitors
    Patent number: 8877772
    Abstract: Provided are compounds having an inhibitory effect on Mixed Lineage Kinases, having a structural Formula, Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment of neuropsychiatric disorders which comprise the inhibition of Mixed Lineage Kinases.
    Type: Grant
    Filed: November 25, 2009
    Date of Patent: November 4, 2014
    Assignee: University of Rochester
    Inventors: Harris A. Gelbard, Stephen Dewhurst, Val S. Goodfellow, Colin Loweth, Torsten Wiemann
  • Bicyclic heteroaryl kinase inhibitors and methods of use
    Patent number: 8846909
    Abstract: Provided are compounds having an inhibitory effect on kinases including Mixed Lineage Kinases. Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions that are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment of neuropsychiatric disorders that comprise the inhibition of Mixed Lineage Kinases.
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: September 30, 2014
    Assignee: University of Rochester
    Inventors: Harris A. Gelbard, Stephen Dewhurst, Val S. Goodfellow, Torsten Wiemann, Satheesh Babu Ravula, Colin J. Loweth
  • MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS
    Publication number: 20140256733
    Abstract: Provided herein are imidazopyridine compounds having an inhibitory effect on mixed lineage kinases (MLKs), methods of their synthesis, and methods of their therapeutic. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and pharmaceutical compositions.
    Type: Application
    Filed: March 7, 2014
    Publication date: September 11, 2014
    Applicant: Califia Bio, Inc.
    Inventors: VAL S. GOODFELLOW, THONG X. NGUYEN, SATHEESH B. RAVULA, HARRIS A. GELBARD
  • BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE
    Publication number: 20130203755
    Abstract: Provided are compounds having an inhibitory effect on kinases including Mixed Lineage Kinases. Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions that are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment of neuropsychiatric disorders that comprise the inhibition of Mixed Lineage Kinases.
    Type: Application
    Filed: May 24, 2011
    Publication date: August 8, 2013
    Applicant: UNIVERSITY OF ROCHESTER
    Inventors: Harris A. Gelbard, Stephen Dewhurst, Val S. Goodfellow, Torsten Wiemann, Satheesh Babu Ravula, Colin J. Loweth
  • MLK INHIBITORS AND METHODS OF USE
    Publication number: 20120053175
    Abstract: Provided are compounds having an inhibitory effect on Mixed Lineage Kinases. Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment of neuropsychiatric disorders which comprise the inhibition of Mixed Lineage Kinases.
    Type: Application
    Filed: November 25, 2009
    Publication date: March 1, 2012
    Applicant: UNIVERSITY OF ROCHESTER
    Inventors: Harris A. Gelbard, Stephen Dewhurst, Val S. Goodfellow, Colin J. Loweth, Torsten Wiemann
  • Cysteine protease inhibitors
    Patent number: 6004933
    Abstract: The present invention relates to cysteine protease inhibitors of the general formula (I): ##STR1## wherein Z is a cysteine protease binding moiety; X and Y are S, O or optionally substituted N; and R.sub.1 is optionally substituted alkyl or aryl.
    Type: Grant
    Filed: April 23, 1998
    Date of Patent: December 21, 1999
    Assignee: Cortech Inc.
    Inventors: Lyle W. Spruce, Albert C. Gyorkos, John C. Cheronis, Val S. Goodfellow, Axel H. Leimer, John M. Young, James Ivan Gerrity
  • Method for preparing and identifying N-substitued 1,4-piperazines and N-substituted 1,4-piperazinediones
    Patent number: 5811241
    Abstract: The invention provides a method of synthesizing N-substituted 1,4-piperazines and N-substituted 1,4-piperazinediones. The invention also provides a method for synthesing combinatorial libraries of piperazine derivatives which can be assayed for biological activity in pre-specified ligand binding or enzymatic activity screens.
    Type: Grant
    Filed: September 13, 1995
    Date of Patent: September 22, 1998
    Assignee: Cortech, Inc.
    Inventors: Val S. Goodfellow, Donald A. McLeod, James Ivan Gerrity, Christopher P. Laudeman, Michael R. Burkard
  • Bradykinin antagonists with extended hydrophobic side chains
    Patent number: 5750506
    Abstract: Bradykinin antagonists, particularly Cys.sup.6 analogs, which have an extended hydrophobic side chain.
    Type: Grant
    Filed: May 13, 1996
    Date of Patent: May 12, 1998
    Assignee: Cortech, Inc.
    Inventors: Val S. Goodfellow, Heather B. Kroona, Eric T. Whalley, Francine E. Wincott, Dana A. Zummach
  • Bradykinin antagonist peptides incorporating N-substituted glycines
    Patent number: 5700779
    Abstract: The present invention provides bradykinin type peptides containing N-substituted glycines, particularly bradykinin antagonist peptides useful for the treatment of conditions mediated by bradykinin including pain and inflammation.
    Type: Grant
    Filed: June 20, 1996
    Date of Patent: December 23, 1997
    Assignee: Cortech, Inc.
    Inventors: Val S. Goodfellow, Manoj V. Marathe, Eric T. Whalley, Timothy D. Fitzpatrick, Karen G. Kuhlman
  • Bradykinin receptor antagonists with neurokinin receptor blocking activity
    Patent number: 5610140
    Abstract: The present invention provides a heterodimeric compound possessing bradykinin and neurokinin receptor antagonist activities useful in the treatment of asthma and other inflammatory diseases especially those involving the airway or pulmonary system. The present invention is also useful in the treatment of pain and inflammation.
    Type: Grant
    Filed: August 1, 1994
    Date of Patent: March 11, 1997
    Assignee: Cortech, Inc.
    Inventors: Val S. Goodfellow, Eric T. Whalley, Francine E. Wincott
  • Purinyl and pyrimidinyl tetrahydrofurans
    Patent number: 5272152
    Abstract: Antiviral activity is exhibited by compounds having the formula ##STR1## and its pharmaceutically acceptable salts.
    Type: Grant
    Filed: June 24, 1991
    Date of Patent: December 21, 1993
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Robert Zahler, Val S. Goodfellow